Navigation Links
New research to cut animal testing

Researchers at The University of Manchester have been awarded £130,000 to develop new techniques to reduce the need for animals in drug testing.

Current checks to establish whether a new drug is carcinogenic can be inconclusive and require further testing on live animals to establish whether they are harmful or not.

Dr Richard Walmsley and colleagues at the University spin-out company he founded, Gentronix, have developed techniques using cultured human cells to more effectively weed out cancer-causing compounds.

"The current pre-animal tests that are used are highly sensitive and so most carcinogens are identified," said Dr Walmsley, who is based in the Faculty of Life Sciences.

"Unfortunately, such tests have poor specificity and a lot of safe compounds are also wrongly identified as potential carcinogens. This means that animal testing is still carried out, in case such compounds turn out to be safe.

"The testing process developed at Gentronix has proven very reliable at telling us whether a drug will cause cancer but some chemicals, called promutagens, only become carcinogenic once they have passed through the body's liver.

"This grant will help us develop new non-animal experiments to identify these other toxic compounds and so reduce the need for animal testing."

The funding ?awarded by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) ?will help the scientists establish new genotoxicity tests using cultured human liver cells.

It is hoped the new test will not only reduce the number of compounds that are tested on animals but also ensure harmless chemicals that could prove to be useful new drugs are not falsely labelled as carcinogens.

"I don't believe that animal testing will disappear from drug safety assessment in the short term as you can't ask human volunteers to take novel drugs straight from testing done in tube tests," said Dr Walmsley.

"But if we can refine the pre-animal tests and increase people's confidence in them, then we will be able to reduce the number of chemicals that are tested on live animals."


'"/>

Source:University of Manchester


Related biology news :

1. Columbia research lifts major hurdle to gene therapy for cancer
2. U of M researcher examines newly emerging deadly disease
3. NYU researchers simulate molecular biological clock
4. First atlas of key brain genes could speed research on cancer, neurological diseases
5. New research questions basic tenet of neuron function
6. Vital step in cellular migration described by UCSD medical researchers
7. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
8. UCSD researchers maintain stem cells without contaminated animal feeder layers
9. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
10. New protein discovered by Hebrew University researchers
11. First real-time view of developing neurons reveals surprises, say Stanford researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... , Feb. 23, 2017 /PRNewswire/ - The Fight ... for Cancer Research (OICR) are pleased to report that ... A financing, with Johnson & Johnson Innovation – JJDC, ... include venture groups HealthCap, TPG Biotechnology Partners, and Genesys ... ...
Breaking Biology Technology: